Table 3 Results from clinical samples (a); results from the analysis of positive samples (b); and results for the recovery of different concentrations of AIV H9 from clinical samples (c)
(a) Method | Total number of samples | Number of positive samples | Positivity rate (%) |
---|---|---|---|
Proposed immunosensor | 98 | 3 | 3.06 |
Virus isolation | 98 | 3 | 3.06 |
(b) No | Results from the proposed immunosensor | Results of virus isolation | ||
---|---|---|---|---|
Measured concentration (EID50 mL−1) | Average (EID50 mL−1) | RSD (%) (n = 5) | ||
1 | 60.24, 57.31, 62.17, 63.54, 64.49 | 61.55 | 4.63 | Positive |
2 | 141.25, 137.86, 143.74, 136.47, 142.18 | 140.30 | 2.17 | Positive |
3 | 192.67, 188.34,193.28, 187.59, 195.73 | 191.52 | 1.80 | Positive |
(c) No | Initial AIV H9 concentration in the sample (EID50 mL−1) | Added amount of AIV H9 (EID50 mL−1) | Total found | Recovery rate (%) (n = 5) | |
---|---|---|---|---|---|
Average (EID50 mL−1) | RSD (%) (n = 5) | ||||
1 | 61.55 | 100.00 | 169.03 | 3.47 | 104.63 |
2 | 61.55 | 150.00 | 206.93 | 2.73 | 97.82 |
3 | 140.30 | 200.00 | 326.74 | 4.07 | 96.02 |
4 | 140.30 | 250.00 | 381.37 | 2.17 | 97.71 |
5 | 191.52 | 300.00 | 497.31 | 4.18 | 101.18 |
6 | 191.52 | 400.00 | 584.62 | 3.75 | 98.83 |